EC Number   |
Posttranslational Modification |
Reference |
|---|
    6.1.1.6 | glycoprotein |
mannose and acetylglucosamine |
498 |
| 6.1.1.6 | glycoprotein |
nearly 14% w/w, mannose, fucose, glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine |
495 |
| 6.1.1.6 | lipoprotein |
high molecular weight aminoacyl-tRNA synthetase complex contains lipid. Delipidation does not affect the size or activity of the complex, but a variety of functional and structural properties of individual synthetases in the complex are altered: sensitivity to salts plus detergents, temperature inactivation, hydrophobicity, sensitivity to protease digestion |
127 |
| 6.1.1.6 | phosphoprotein |
in response to immunological challenge of mast cells, LysRS is phosphorylated on residue Ser207 in a MAPK-dependent manner, released from the multisynthetase complex, and translocated into the nucleus |
705725 |
| 6.1.1.6 | phosphoprotein |
phosphorylated KRS is released from multitRNA synthetase complex (MSC) and transölocates to the plasma membrane |
744423 |
| 6.1.1.6 | phosphoprotein |
Ser207-phosphorylation inactivates the enzyme translationally, but activates its transcriptional function |
728305 |
| 6.1.1.6 | phosphoprotein |
the MAPK-ERK pathway leads to the phosphorylation of LysRS on Ser207 and its release from the MSC in activated mast cells. Phosphorylation of Ser207 can be inhibited by U0126 treatment |
745950 |
| 6.1.1.6 | proteolytic modification |
prior of packing of the enzyme into viral particles, it is truncated independent of viral protease |
653072 |
| 6.1.1.6 | proteolytic modification |
the enzyme is N-terminally cleaved during incorporation into HIV particles |
652421 |
